We have also demonstrated that GA therapy, whose effects require CD8+ T-cells in mice (64), was able to increase the induction of CD4+CD25+ Tregs from the CD4+CD25− T-cell population in MS patient blood (40). This evidence concerns the gene CD8A and myeloid sarcoma.